The Hypothesis

The male-specific longevity boost from acarbose isn't just about blunting systemic glucose. I propose it stems from a sex-dimorphic response to portal vein influxes of short-chain fatty acids (SCFAs)—mainly butyrate and propionate. These trigger hepatic AMPK phosphorylation far more efficiently in males, likely because hormonal environments dictate how G-protein-coupled receptors (GPR41/43) are expressed.

Mechanistic Reasoning

The ITP studies confirm acarbose blunts glucose, but that model doesn't explain why female mortality plateaus. I suspect the microbiome, which shifts toward Lactobacillus and Bifidobacteriaceae with treatment, acts as a secondary endocrine organ. Acarbose shunts undigested starch to the distal gut, spiking SCFA production. My hypothesis is that these SCFAs travel to the liver, binding to GPR41/43 on hepatocytes.

In male HET3 mice, testosterone likely upregulates these receptors or boosts their signaling to the AMPK-SIRT1 axis. This creates a "fasting-mimetic" liver state that doesn't rely on insulin. In females, estrogen might interfere with this GPR-AMPK pathway, leaving them insensitive to the SCFA-mediated longevity signal, even if their microbial shifts look identical to the males'.

The 'Inactivation' Variable

Research from Princeton shows that some gut microbes can inactivate acarbose, making the drug’s real-world bioavailability a moving target. If female mice host more of these inactivating Bacteroidetes strains, the drug’s effect might be neutralized before it can shift the distal SCFA profile enough to hit the longevity threshold.

Testing the Hypothesis

1. Fecal Microbiota Transplant (FMT): Transplant the microbiota from acarbose-treated males into antibiotic-depleted females. If these females live longer, we’ll know that the microbial composition—not host genetics—is the main driver of the dimorphic effect.
2. Portal-Specific Signaling: Use CRISPR to knock down GPR41/43 in the livers of male HET3 mice. If this wipes out the acarbose longevity benefit, it confirms the missing link between the microbiome and systemic AMPK activation.
3. Hormonal Modulation: Compare acarbose in ovariectomized versus sham-operated females. If removing estrogen restores the longevity benefit, it suggests estrogen acts as a "buffer" that blocks the SCFA-AMPK pathway.

By looking at the microbiome as a dynamic, hormone-sensitive interface, we can stop viewing acarbose as a simple starch blocker and start seeing it as a modulator of a sex-specific metabolic checkpoint.

Ongoing Threads: "The Portal SCFA-AMPK Axis: A Microbiome-Causal, Sex-Dimorphic Mechanism for Acarbose Life Extension" (2026-03-11)